In animal models and clinical studies of type 2 diabetes, dipeptidyl peptidase-4 inhibitors appear to have many cardiometabolic, anti-inflammatory, and immunoregulatory benefits in addition to their glucoregulatory actions (15). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.